Cholinergic Markers Alzheimer's Disease (CHOLINE)
Cholinergic Markers as Predictive Tools of Therapeutic Response in Alzheimer's Disease (CHOLINE)
Several previous studies have assessed acetylcholine (Ach) and acetylcholinesterase activity (AchE-a) levels in Alzheimer's disease (AD) pathophysiology. The cerebrospinal fluid (CSF) Ach level was significantly decreased in AD patients, and correlated positively with dementia score and MMSE (1, 2). Two studies have demonstrated positive correlations between CSF AchE-a and CSF Tau, phosphorylated-Tau (P-Tau) and AB 1-42 peptide (3,4). ChEIs (cholinesterase inhibitors) have been approved for the treatment of AD but only 20 to 30 % of patients are responders (5). Any consistent data allow the clinician to predict the response to the treatment. The link between basal cholinergic status and ChEIs efficiency has never been done. Even if, there is a wild research in AD treatment, ChEIs or treatment acting on the Ach pathways will remain a long time valuable treatment particularly in moderate AD in which disease modifying therapies did not show any efficiency.
The investigators's objective is to prospectively explore the predicting value of CSF Ach and AchE-a levels on ChEIs response in AD patients.
調査の概要
詳細な説明
Strategy: Within the framework of the usual management, the investigators propose the protocol to patients who had an assay of the CSF biomarkers with a CSF AD biological profile before the introduction of an IChEs and having accepted Their CSF will stocked in our biobank. Patients will only have additional neuropsychological assessments. The rest of the care comes under the current care.
The quantification of ACh in the CSF will be performed in tandem mass spectrometry after separation by liquid chromatography (LC-MS / MS). AChE activity will be determined by colorimetric determination.
The investigators's objective is to prospectively explore the predicting value of CSF Ach and AchE-a levels on ChEIs response in AD patients.
The evaluation criteria will be
- Difference of the mean value of the ACh level and AChE activity in the CSF between the responder and non-respondier groups of patients.
- "Responder" patients are defined by an improvement of at least 4 points on the ADAS-Cog (cognitive part) ADAS-Cog after 6 months of treatment.
- "Non-responders" are defined as aggravation, lack of improvement or improvement <4 points on the ADAS-Cog scale.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Paris、フランス、75010
- Centre Mémoire de Ressources et de Recherche Paris Nord
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Inclusion criteria :
- Male or Female aged ≥ 50 years
- Patients with a biological profile of CSF biomarkers in favor of Alzheimer's disease
- Alzheimer's disease diagnosed according to McKahnn 2011 criteria [1] at mild to moderate stage Clinical Dementia Rating (CDR) ≤2
- Indication to treatment with inhibitor of acetycholinesterase
- Patients benefiting from national health coverage
- Patients not subject to legal protection
- Fluent in French language
Exclusion criteria :
- No indication or contraindication to PL
- Contraindications to IChEs
- Patient included in other anti-Alzheimer drug clinical trial
- Clinical Dementia Rating CDR> 2
- Another cause of neurocognitive decline
- Serious psychiatric disorders
- Other serious life-threatening conditions
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
Alzheimer disease patients
|
Neuropsychological test
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Neuropsychological test (ADASCog)
時間枠:between baseline and month 6
|
"Responder" patients are defined by an improvement of at least 4 points on the ADAS-Cog (cognitive part) ADAS-Cog after 6 months of treatment.
"Non-responders" are defined as aggravation, lack of improvement or improvement <4 points on the ADAS-Cog scale
|
between baseline and month 6
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
時間枠:month 6
|
Alzheimer disease (AD)
|
month 6
|
Difference of CSF Ach AND AChE activity between responder and non responder groups
時間枠:month 6
|
biological test
|
month 6
|
Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
時間枠:month 6
|
biological test
|
month 6
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
アルツハイマー病の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ